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Ovarian Sertoli-Leydig cell tumors (SLCTs) are the most fre-
quently observed low-grade malignancies.1-3 SLCTs have been 
classified into well differentiated (grade 1), intermediate dif-
ferentiation (grade 2), and poorly differentiated tumors (grade 
3).4-7 Although surgery plays the most pivotal role in the man-
agement of patients with SLCT, postoperative adjuvant plati-
num-based chemotherapy is indicated in advanced tumors 
and in poorly differentiated SLCTs. Clinical data evaluating 
the benefit of chemotherapy and the optimal regimen, how-
ever, are limited, with most of the literature consisting of an-
ecdotal case reports.8,9 We hypothesized that adjuvant chemo-
therapy could be safely avoided in patients with low-grade 
SLCTs and would lead to more successful clinical results, there-
by improving fertility and prognostic outcomes. The present 
study was approved by Institutional Review Board for Human 
Research of Yonsei University Hospital (ethic code: 4-2020-
0395). The medical records of 24 patients who were pathologi-
cally diagnosed with SLCTs of the ovary were reviewed. All pa-
tients were treated at two institutes from 2006 to 2019.10 Based 
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The purpose of the current study was to compare prognostic outcomes between patients with high-grade ovarian Sertoli-Leydig 
cell tumors (SLCTs) and those with other low-grade SLCTs. We retrospectively reviewed medical records for 24 patients patholog-
ically diagnosed with SLCTs between 2006 to 2019 at two institutions. The patients were grouped according to pathological grade: 
SLCT was classified as grade 1, well differentiated; grade 2, intermediated differentiated; or grade 3, poorly differentiated (Meyer’s 
classification). Statistical analysis was performed to compare survival outcomes according to pathological grade. The median pa-
tient age was 42.5 years (range 16–75). Eighteen patients (75%) were International Federation of Gynecology and Obstetrics stage 
I, and none were diagnosed in stage IV. Nine patients (37.5%) were grade 3, and 15 patients (63.5%) were grades 1–2. When com-
paring clinical baseline characteristics of the grade 1–2 group with those of the grade 3 group, only serum CA125 level at diagnosis 
was significantly higher in the grade 3 group (38.34 vs. 382.29, p=0.002). Five patients experienced recurrence of grade 3 disease, 
while no recurrence was reported in grade 1–2 disease. Four of the five recurrent patients died. In result, grade 3 ovarian SLCT 
showed significantly poorer prognosis than grade 1–2 disease (overall survival, hazard ratio=14.25, 95% confidence interval= 
1.881–108.0; log-rank p=0.010). Our findings were consistent with the concept that patients with stage I/grade 1–2 tumors have a 
good prognosis without adjuvant chemotherapy. Since grade 3 ovarian SLCT appears to be relatively more fatal than grade 1 or 2, 
patients with grade 3 SLCT might require more aggressive surgical intervention and post-treatment surveillance.
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on a histopathological review, the cases were divided into one 
of the three SLCT categories: grade 1 tumors were well differen-
tiated and contained a significant component of Leydig cells, as 
well as Sertoli cells. Grade 2 tumors exhibited intermediate dif-
ferentiation, and tumors were composed of immature Sertoli 
cells typically arranged in a diffuse pattern. Grade 3 tumors 
were poorly differentiated, and increased mitotic activity and 
only a few Leydig cells were found (Fig. 1).11 The median pa-
tient age was 42.5 years (range 16–75). The age distribution of 
the patients with grade 3 disease was not significantly different 
from those with grade 1–2 disease. International Federation of 
Gynecology and Obstetrics stages were as follows: 18 (75.0%) 
with stage I, 4 (16.7%) with stage II, 2 (8.3%) with stage III, and 
none with stage IV. Six patients (25.0%) had grade 1 tumors, 
9 (37.5%) had grade 2 tumors, and 9 (37.5%) had grade 3 tu-
mors. Two cases contained heterologous elements: patients had 
IA/G3 and IIIC/G3 diseases, respectively. Overall, 9 patients 
(37.5%) had grade 3 and 15 patients (63.5%) had grade 1–2 
disease. When comparing clinical baseline characteristics of 
patients with grade 1–2 disease with those with grade 3 dis-
ease, only serum CA125 level at diagnosis was significantly 
higher in the grade 3 group (38.34 vs. 382.29, p=0.002) (Table 
1). Fertility-preservation intervention was performed in 14 
(58.3%) patients (laparoscopic approach in six cases), while de-
finitive surgery was executed in 10 (47.7%) patients. Ten pa-
tients had staging surgery that included total abdominal or 
laparoscopic hysterectomy with bilateral salpingo-oophorec-
tomy. Additionally, 8 of 24 patients underwent pelvic lymph 
node dissections. Eight of the 24 patients underwent laparo-




Fig. 1. Pathologic comparison of ovarian Sertoli-Leydig cell tumor by pathologic grade. (A) Grade 1. Tubules of Sertoli cell and clusters of Leydig cell in in-
tervening stroma are shown. Sertoli cells with oval to round nuclei and Leydig cells with eosinophilic cytoplasm are characterized. No atypia or mitotic 
activity is observed. (B) Grade 2. Typical diffuse or lobulated architectural pattern and alternating hypo and hypercellularity are observed. Hyperchromat-
ic, oval or spindled nuclei with mild to moderate atypia are characterized. (C) Grade 3. Diffuse sheets of immature cells with moderate to marked nuclear 
atypia are observed. Increased mitotic activity and few Leydig cells are found.
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patients were given adjuvant chemotherapy after surgery, 
consisting of a bleomycin, etoposide, and cisplatin regimen in 
eight cases and a combined paclitaxel and cisplatin regimen 
in one case. Fourteen patients who had IA/grade 1, IA/grade 
2, or IC disease were not administered postoperative chemo-
therapy. Five of the 24 patients experienced disease recur-
rence, and four patients died from recurrence after surgery. Of 
note, the tumors from these 2 patients were pathologically re-
diagnosed as Sertoli-form endometrioid carcinoma. The other 
20 patients remain alive without evidence of recurrence at the 
time of reporting (Table 2). The 5 patients with recurrence all 
had grade 3 disease, and no recurrence was reported in grade 
1–2 disease. As a result, grade 3 ovarian SLCT showed signifi-
cantly poor prognosis than grade 1–2 disease (overall survival, 
hazard ratio=14.25, 95% confidence interval=1.881–108.0; log-
rank p= 0.010) (Fig. 2).
The present study was performed to compare prognostic 
outcomes between patients with high-grade SLCTs and those 
with other low-grade SLCTs. Our results revealed that patients 
with stage I/ grade 1–2 tumors have an excellent prognosis 
without adjuvant chemotherapy. Since grade 3 ovarian SLCT 
appears to be relatively more fatal than grade 1 or 2, grade 3 
SLCT may warrant more aggressive surgical intervention and 
postoperative chemotherapy. Overall, the prognoses of patients 
Table 1. Baseline and Disease Characteristics
Grade 1–2 (n=15) Grade 3 (n=9) Total (n=24) p value
Age (yr) 0.164
Mean±SD 48.40±18.27 36.48±19.32 54.04±19.13
Median (range) 51 (20–72) 31 (16–75) 42.50 (16–75)
BMI (kg/m²) 0.153
Mean±SD 28.01±4.44 22.78±3.55 2409±4.36
Median (range) 24.89 (19.03–35.86) 22.68 (17.40–28.72) 23.07 (17.40–35.86)
Parity 0.246
Mean±SD 1.27±1.22 0.67±0.87 1.04±1.12
Median (range) 2 (0–4) 0 (0–2) 1 (0–4)
Menopause, n (%) 0.423
Premenopause 7 (46.7) 6 (66.7) 13 (54.2)
Postmenopause 8 (53.3) 3 (33.3) 11 (45.8)
FIGO stage, n (%) 0.112
I 13 (86.7) 5 (55.6) 18 (75.0)
II 2 (13.3) 2 (22.2) 4 (16.7)
III 0 (0) 2 (22.2) 2 (8.3)
IV 0 (0) 0 (0) 0 (0)
LN metastasis, n (%) 0.320
Negative 14 (93.3) 8 (88.9) 22 (91.7)
Positive 1 (6.7) 1 (11.1) 2 (8.4)
CA-125 (U/mL) 0.002
Mean±SD 38.34±42.55 382.29±550.48 167.32±368.01
Median (range) 24.30 (7.5–157.3) 134.40 (4.0–1512.9) 27.85 (4.0–1521.9)
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node.
Table 2. Adjuvant Chemotherapy and Prognostic Outcome
Stage n
Adjuvant chemotherapy Recurrence Status
Yes No Yes No NED DOD
I G1   5 0   5 0   5   5 0
I G2   8 0   8 0   8   8 0
I G3   5 4   1 1   4   4 1
II G1   1 0   1 0   1   1 0
II G2   1 1   0 0   1   1 0
II G3   2 2   0 2   0   1 1
III G3   2 2   0 2   0   0 2
Total 24 9 15 5 19 20 4
NED, no evidence of disease; DOD, died of disease.
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were favorable in our study, even for patients who did not re-
ceive adjuvant chemotherapy, and laparoscopy was a feasible 
approach to treat this disease. 
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Fig. 2. Kaplan-Meier curves of progression-free survival (A) and overall survival (B) between patients with high-grade SLCTs (n=9) and low-grade 
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